Skip to main content
. 2022 Oct 14;109(11):2029–2048. doi: 10.1016/j.ajhg.2022.09.013

Table 1.

Overview of cCREs in the PRDM13 and IRX1 loci

cCRE Coordinates (hg38) cCRE characteristics In vitro luciferase assay In vivo enhancer detection assay
PRDM13 locus

PRDM13_cCRE1 chr6:99,588,208–99,589,239 UMI-4C peak, DHS, ChIP-seq (H3K4me2, CRX, NRL, OTX2) not significant eye and brain
PRDM13_cCRE2 chr6:99,590,566–99,591,414 UMI-4C peak, DHS ND ND
PRDM13_cCRE3 chr6:99,592,841–99,593,364 Mutational hotspot-1, DHS, ChIP peak (CRX, OTX2) positive no activity
PRDM13_cCRE4 chr6:99,595,852–99,596,746 UMI-4C peak, DHS ND ND
PRDM13_cCRE5 chr6:99,598,651–99,599,224 Mutational hotspot-2, UMI-4C peak, DHS not significant eye and brain
PRDM13_cCRE6 chr6:99,617,828–99,619,867 UMI-4C peak, DHS, ChIP-seq (H3K27me2) positive ND
PRDM13_cCRE7 chr6:99,645,605–99,647,017 UMI-4C peak, DHS, highly conserved region ND ND
PRDM13_cCRE8 chr6:99,749,318–99,752,123 UMI-4C peak, DHS, ChIP-seq (H3K4me2, H3K27ac), UCNE not significant ND

IRX1 locus

IRX1_cCRE1 chr5:3,224,667–3,227,420 UMI-4C peak, DHS, ChIP-seq (H3K4me2, H3K27ac), UCNE positive ND
IRX1_cCRE2 chr5:3,426,706–3,428,595 UMI-4C peak, DHS, UCNE positive ND
IRX1_cCRE3 chr5:3,488,008–3,490,747 UMI-4C peak, DHS, ChIP-seq (H3K27ac), UCNE positive ND
IRX1_cCRE4 chr5:3,529,207–3,531,844 UMI-4C peak, UCNE negative ND
IRX1_cCRE5 chr5:3,620,470–3,622,600 UMI-4C peak, DHS negative ND
IRX1_cCRE6 chr5:3,628,385–3,630,819 UMI-4C peak, DHS, conserved region not significant ND
IRX1_cCRE7 chr5:3,649,694–3,651,723 UMI-4C peak, DHS, conserved region positive eye, brain, neural crest
IRX1_cCRE8 chr5:3,729,667–3,732,532 UMI-4C peak, DHS, conserved region positive ND
IRX1_cCRE9 chr5:3,786,388–3,788,778 UMI-4C peak, DHS, conserved region ND ND
IRX1_cCRE10 chr5:4,424,583–4,425,559 shared duplicated region, DHS, UCNE not significant eye and brain

The cCREs are obtained after integration of the UMI-4C profiles in the retina-specific multi-omics database (Figure S3). For each cCRE, it is indicated which characteristics contributed to their identification. The two right columns indicate whether cCRE activity was assessed using in vitro luciferase assays or in vivo enhancer detection assays, as well as the outcome of these experiments. When the cCRE of interest was not determined using in vitro luciferase assays or in vivo enhancer detection assays, this is indicated by ND. cCRE, candidate CRE; DHS, DNase I hypersensitive site; ChIP-seq, chromatin immunoprecipitation sequencing; ND, not determined; UCNE, ultraconserved non-coding element.